4/18
08:00 am
bpmc
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Low
Report
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
4/11
08:14 am
bpmc
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics [Yahoo! Finance]
Low
Report
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics [Yahoo! Finance]
4/11
08:00 am
bpmc
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
Medium
Report
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
4/10
11:20 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $114.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $114.00 price target on the stock.
4/4
04:01 pm
bpmc
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/29
07:34 am
bpmc
Blueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven? [Yahoo! Finance]
Low
Report
Blueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven? [Yahoo! Finance]
3/14
08:25 am
bpmc
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer [Yahoo! Finance]
Medium
Report
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer [Yahoo! Finance]
3/6
04:01 pm
bpmc
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/28
06:04 am
bpmc
Kate Haviland [CNBC]
Medium
Report
Kate Haviland [CNBC]
2/26
08:09 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $97.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $97.00 price target on the stock.
2/23
08:21 am
bpmc
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting [Yahoo! Finance]
Medium
Report
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting [Yahoo! Finance]
2/23
08:00 am
bpmc
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
Low
Report
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
2/21
08:26 pm
bpmc
InnovationRx: Blueprint Says It's Rare Disease Drug Could Be A Blockbuster [Forbes]
Low
Report
InnovationRx: Blueprint Says It's Rare Disease Drug Could Be A Blockbuster [Forbes]
2/16
03:40 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $114.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $114.00 price target on the stock.
2/16
12:38 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Citigroup Inc. from $54.00 to $65.00. They now have a "sell" rating on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Citigroup Inc. from $54.00 to $65.00. They now have a "sell" rating on the stock.
2/16
09:39 am
bpmc
Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/16
07:07 am
bpmc
Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines [Yahoo! Finance]
Low
Report
Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines [Yahoo! Finance]
2/15
03:02 pm
bpmc
Blueprint Medicines Stock Jumps on Rise in Ayvakit Sales [MarketWatch]
Low
Report
Blueprint Medicines Stock Jumps on Rise in Ayvakit Sales [MarketWatch]
2/15
08:05 am
bpmc
Blueprint Medicines Corp Reports Robust AYVAKIT Revenue Growth in Q4 and Full Year 2023 [Yahoo! Finance]
High
Report
Blueprint Medicines Corp Reports Robust AYVAKIT Revenue Growth in Q4 and Full Year 2023 [Yahoo! Finance]
2/15
07:19 am
bpmc
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results [Yahoo! Finance]
High
Report
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results [Yahoo! Finance]
2/15
07:00 am
bpmc
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
High
Report
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
2/13
09:24 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Barclays PLC from $58.00 to $70.00. They now have an "equal weight" rating on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Barclays PLC from $58.00 to $70.00. They now have an "equal weight" rating on the stock.
2/12
11:10 am
bpmc
Seeking Clues to Blueprint Medicines (BPMC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics [Yahoo! Finance]
Low
Report
Seeking Clues to Blueprint Medicines (BPMC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics [Yahoo! Finance]
2/12
05:15 am
bpmc
Lauren Barnes Joins Ossium Health's Board of Directors [Yahoo! Finance]
Low
Report
Lauren Barnes Joins Ossium Health's Board of Directors [Yahoo! Finance]
2/5
05:10 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $97.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $97.00 price target on the stock.